HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study
Vivek Naranbhai(Centre for Human Genetics), Mary Carrington(Ragon Institute of MGH, MIT and Harvard), Stefan Groha(Dana-Farber Cancer Institute), Xinmeng Jasmine Mu(Pfizer (United States)), Alexander Gusev(Dana-Farber Cancer Institute), Kevin M. Chin(Merck (Germany)), Toni K. Choueiri(Harvard University), Michael Dean(National Cancer Institute), Yuko Yuki(Frederick National Laboratory for Cancer Research), Paul B. Robbins(Pfizer (United States)), David A. Braun(Yale Cancer Center), James L. Gulley(National Cancer Institute), Mathias Viard(National Cancer Institute), Sachet A. Shukla(Broad Institute), Chris Labaki(Beth Israel Deaconess Medical Center), Megan Wind‐Rotolo(Bristol-Myers Squibb (United States)), Parantu K. Shah(Ono Pharmaceutical (United States))
Cited by 126
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Integrative approaches for large-scale transcriptome-wide association studies
|Nature Genetics|2016|2.7k